Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)


ACTIV Executive Committee

The ACTIV Executive Committee is made up of representatives from various agencies of the U.S. government and pharmaceutical companies.2)

Preclinical Working Group

Name Organization Role
Peter Adams3) Department of Health of Human Services (HHS) Health Scientist, Influenza Division; Biomedical Advanced Research and Development Authority
Annaliesa Anderson Pfizer Vice President and Chief Scientific Officer, Bacterial Vaccines
James Anderson National Institutes of Health (NIH) Director, Division of Program Coordination, Planning, and Strategic Initiatives; Office of the Director
Ralph Baric University of North Carolina Professor, Deptartment of Epidemiology and Deptartment of Microbiology and Immunology
Kara Carter Dewpoint Therapeutics Senior Vice President, Discovery Biology
Marc Charette National Heart, Lung, and Blood Institute Program Director; Division of Cardiovascular Diseases
Tomas Cihlar Gilead Sciences Vice President and Head of Virology
Christine Colvis National Center for Advancing Translational Sciences Director, Drug Development Partnership Programs]]
Michael Diamond Washington University School of Medicine in St. Louis The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology
Ken Duncan Bill & Melinda Gates Foundation Deputy Director, Discovery – Therapeutics
Prabhavathi Fernandes National Biodefense Science Board SAC of GARDP, Chair
Joshua Fessel National Heart, Lung, and Blood Institute Program Director, Lung Vascular Biology Program; Division of Lung Disease
Clint Florence National Institute of Allergy and Infectious Diseases (NIAID) Program Officer, Research Resource Section, OBRR, DMID
Greg Gatto RTI International Drug Development Regulatory Project Leader
Jay Grobler Merck Executive Director, Infectious Disease and Vaccines
Nancy Haigwood Oregon National Primate Research Center; Oregon Health & Science University Director and Professor
Judith Hewitt National Institute of Allergy and Infectious Diseases (NIAID) Deputy Director, Office of Biodefense, Research Resources and Translational Research
Sheri Hild National Institutes of Health (NIH) Program Director for National Primate Research Centers; Office of Research and Infrastructure Program
Samantha Jonson National Center for Advancing Translational Sciences Special Assistant to the Director
Isis Kanevsky Pfizer Director
Kent Lloyd University of California, Davis Professor, Department of Surgery, School of Medicine Director, Mouse Biology Program; Associate Director, Comprehensive Cancer Center
Joanne Lumsden National Center for Advancing Translational Sciences Senior Scientific Program Manager, Drug Development Partnership Programs
Cat Lutz Jackson Laboratory Senior Director, Mouse Repository & In Vivo Pharmacology, Rare and Orphan Disease Center
Stephen Mason Pfizer Research Associate & Viral Drug Discovery Fellow
Frank Nestle Sanofi Global Head of Immunology Therapeutic Research Area and Chief Scientific Officer North America
Elizabeth Ottinger National Center for Advancing Translational Sciences Senior Program Manager, Division of Preclinical Innovation
David Payne GlaxoSmithKline Vice President & Head, Medicine Opportunities Research Unit
Louise Pitt United States Army Medical Research Institute of Infectious Diseases Director, Center for Aerobiological Sciences
Antonello Punturieri National Heart, Lung, and Blood Institute Program Director, Division of Lung Diseases
Srinivas Rao Sanofi Global Head, Translational In Vivo Models Global Research Platform
Jay Rappaport Tulane University National Primate Research Center Professor of Microbiology and Immunology; Director and Chief Academic Officer
John Young Roche Global Head Infectious Diseases and Vice President
Roland Zahn Janssen Senior Scientific Director; Head Preclinical Immunology, Viral Vaccines
ACTIV. National Institutes of Health (NIH). Retrieved April 1, 2022, from
Preclinical Working Group. (2022, March 8). National Institutes of Health (NIH).